NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026
Estimated value
—
Awarded value
—
Suppliers
33
Lots
2
Published
10 Jul 2026
Description
NHS Branded Medicines Tranche B - Lot 1 - London & South of England - CM/PHR/25/5731 Period of Framework Agreement: 1 September 2026 to 31 August 2028 with an option or option(s) to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Lot 2 - Ustekinumab for North of England and Midlands & East, period of Framework Agreement: 1st September 2026 to 31st August 2027 with an option or option(s) to extend for a further 12 months.
Scope
- Reference
- C414011
- Commercial tool
- Standalone contract
- Contract dates
- 31 Aug 2026 to 31 Aug 2028Possible extension to 31 Aug 2030
With an option or option(s) to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.
- CPV classifications
- 33600000
- Contract locations
- North West England, United KingdomSouth East England, United KingdomSouth West England, United KingdomLondon, United KingdomEast Midlands, United KingdomWest Midlands, United KingdomNorth East England, United Kingdom
- Particular suitability
- Small and medium-sized enterprises (SME)
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| Price is not the only award criterion | Price is not the only award criterion and all criteria are stated only in the procurement documents | price | — |
Submission & procedure
- Procedure
- Open procedure
Award details· 2 awards
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
—
Award date
—
Contract start
—
Contract end
—
Lots · 2 total
Divisions of the contract. Each lot can be awarded separately.
| Lot | Title | Est. value | Status |
|---|---|---|---|
| 1 | Lot 1 - Tranche B for London & South of England | £541.5m | complete |
| 2 | Lot 2 - Ustekinumab for North of England and Midlands & East | £50.9m | complete |